SEC Filings
Enliven Therapeutics Gets FDA Agreement On Leukemia Trial Design As Quarterly Loss Widens
The drug developer expects to begin its first pivotal trial before year-end, with $884.4 million available to fund operations.
SEC Filings
The drug developer expects to begin its first pivotal trial before year-end, with $884.4 million available to fund operations.
SEC Filings
The position covers 3,193,867 shares in the broadband provider, with ownership measured as of September 30.
SEC Filings
Catherine D. Wood is a co-reporting person for the same 8,607,836-share position.
SEC Filings
Scores delivered a 90% segment operating margin in fiscal 2026, while unfinished mortgage-pricing agreements kept 2027 guidance on hold.
SEC Filings
The securities start with a 7.625% interest rate, but a capital trigger would convert them into shares and end HSBC’s obligations.
SEC Filings
The insurer also declared dividends for its Series F and Series G preferred shareholders, payable December 31.
SEC Filings
Rent relief and capital support will help fund modernization, but financing access and restaurant economics will shape the rollout.
SEC Filings
Smelter tax incentives sit alongside disputed assessments and a contractor claim whose potential cost Freeport cannot reasonably estimate.
SEC Filings
Demand declines eased at its main websites, while the company updated its annual outlook after selling two personalized-gift businesses.
SEC Filings
Amtagvi supplied about $102 million in U.S. revenue as production margins improved and the full-year forecast stayed intact.
SEC Filings
The drugmaker lifted its annual outlook for a second consecutive quarter while operating cash flow reached $130.8 million.
SEC Filings
Higher trial costs and licensing milestones increased spending, while its funding outlook depends partly on FDA approval.